Vikki Velasquez is a researcher and writer who has managed, coordinated, and directed various community and nonprofit organizations. She has conducted in-depth research on social and economic issues ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Here’s What’s Entering the Public Domain in 2026 If you want to make a dark and twisted Betty Boop slasher film, have at it.

Micah Castelo is a web editor for EdTech: Focus on K-12. Her experience includes education and community news coverage for the Syracuse Post-Standard and international news reporting for the Pulitzer ...